IL-YANG Pharmaceutical evolves into the world's leading pharmaceutical group through relentless R&D to improve the health of humanity.
1940's
- 1946 Acquired Hanseong Pharmaceutical Company(漢城藥館), and established Gongsin Pharmaceutical Company(共信藥業社) after obtaining the approval from Hanji Medicine Corporation(限地藥鍾商)
1950's
- 1957 Obtained the license for pharmaceutical business, and established Seonrim Pharmaceutical Company
- 1957 Developed and launched “Norumo”, the first product
1960's
- 1961 Renamed to Ilyang Pharmaceutical Industry Corporation
1970's
- 1971 Launched “Wonbi-D”, the ginseng nutritious tonic
- 1972 Exported “Wonbi-D” to Japan
1980's
- 1986 Established the Central Research Institute
1990's
- 1992~1995 Clinical trial for Ilaprazole
- 1997. 12 Obtained the U.S. substance patent for Ilaprazole
- 1998. 11 Obtained the Korean substance patent for Ilaprazole
2000's
- 2001. 12 Entered into the license agreement with China’s Livzon Pharmaceutical for Ilaprazole
- 2007. 05 Multinational phase 3 clinical trial for Ilaprazole (6 South East Asian countries)
- 2007. 10 Completed the phase 2 clinical trial for Ilaprazole’s effect on reflux esophagitis in the United States
- 2007. 12 Obtained the approval of the Ilaprazole sale in China
- 2008. 07 Started the phase 1 clinical trial for radotinib (IY5511)
- 2008. 11 Obtained the approval of Ilaprazole (the nation’s 14th new indigenous drug)
- 2008. 12 Established the SIS Immunology Research Center (Jointly with Sook-myung Women's University -Ilyang Pharmaceutical - Samsung Seoul Hospital),Started the research into new cytokine and new peptide
- 2009. 03 Obtained the U.S. patent for radotinib
- 2009. 07 Started the phase 2 clinical trial for radotinib
- 2009. 12 Launched the Ilaprazole (Noltec tab) (in Korea)
2010's
- 2011. 08 Started the phase 3 clinical trial for radotinib, the primary treatment drug
- 2012. 07 Ilyang submitted the influenza vaccine IND and phase 1 clinical trial IRB
- 2012. 01 Obtained the approval of radotinib(the nation’s 18th new indigenous drug: Supect)
- 2012. 03 SIS Immunology Research Center - Obtained the utilization patent for the invention of components that enhances the hair growth function using the fat stem cells
- 2014. 02 Government held “Transgovernmental Enterprise for Pandemic Influenza in Korea(TEPIK)” Contest In the Final Selection, a New Influenza Vaccine, H7N9 form, Selected as Research Project
- 2014. 05 Respiratory Syncytial Virus(RSV) Treatment Substance Developed
- 2014. 06 Supect, the Result of 24 month of Clinical Phase II Presented at the 19th EHA(European Hematology Association)
- 2014. 07 General Hospital of Beijing, Presented a Paper of Noltec
- 2014. 07 Noltec, First Time Published on Global Medical Journal “AP&T”
- 2014. 08 MOU Signed with College of Medicine KOREA University Research and Institute for Industry Cooperation
- 2015. 01 Initiation of clinical trial phase 1/2a for quadrivalent inactivated Influenza Vaccine (egg-based)
- 2015. 02 SUPECT, early completion of multi-national/multi-center clinical trial phase 3
- 2015. 02 Approved market authorization for IL-YANG Flu Vaccine Vial INJ.(Trivalent inactivated influenza vaccine)
- 2015. 05 SUPECT, Clinical trial result presented at Autumn conference of the Korean Society of Hematology(KSH)
- 2015. 06 “SUPECT” validated as a potential treatment for Acute Myeloid Leukemia(AML)
- 2015. 06 Candidate material for New Drug confirms efficacy on “Ebola Virus”
- 2015. 07 Discover potential “MERS Virus” treatment substance
- 2015. 10 Initiated Phase III Clinical trial for Quadrivalent Influenza Vaccine Super leukemia treatment SUPECT approved for 1st line treatment
- 2015. 12 SUPECT, Orally presented its Final Phase III Clinical Trial Results at 2015 American Society of Hematology (ASH) Annual Meeting
- 2016. 02 SUPECT, Launching Ceremony for 1st Line Therapy
- 2016. 02 IL-YANG PHARM, MOU signed with Gyeongbuk Institute for Bio Industry
- 2016. 03 SUPECT, Presented Phase III Clinical Trial Results at 2016 Highlight of ASH in Asia-Pacific (2016 HOA)
- 2016. 05 IL-YANG, entered MOU with Cha Vaccine R&D Center for cooperate R&D of Flu Vaccines and other New Vaccines.
- 2016. 05 Discovered an effective material for ‘Zika’ and ‘MERS’ virus treatment.
- 2016. 05 Development of ‘Prion Diseases Treatment’ has been selected as research project of Ministry of Health and Welfare.
- 2016. 05 New influenza vaccine research project finally selected as governments’ “Infectious diseases crisis management technology development“ contest.
- 2016. 06 ‘H7N9 Vaccine’ Avian Influenza vaccine, presented at 35th American Society for Virology (ASV) Annual Meeting.
- 2016. 07 Development of MERS virus treatment, selected as governmental research project